Take a look at the Recent articles

Associations of a SHROOM3 variant with mild renal impairment and depressive symptomsin a Chinese Han population

Guo-Ping Shi

Rugao People’s Hospital, Rugao, Jiangsu, China

Fudan University- the People's hospital of Rugao Joint Research Institute of Longevity and Aging, China

E-mail : aa

Xue-Feng Chu

Rugao People’s Hospital, Rugao, Jiangsu, China

Fudan University- the People's hospital of Rugao Joint Research Institute of Longevity and Aging, China

Yin-Sheng Zhu

Rugao People’s Hospital, Rugao, Jiangsu, China

Fudan University- the People's hospital of Rugao Joint Research Institute of Longevity and Aging, China

Jiang-Hong Guo

Rugao People’s Hospital, Rugao, Jiangsu, China

Fudan University- the People's hospital of Rugao Joint Research Institute of Longevity and Aging, China

Yong Wang

Rugao People’s Hospital, Rugao, Jiangsu, China

Fudan University- the People's hospital of Rugao Joint Research Institute of Longevity and Aging, China

Jian-Ming Shi

Rugao People’s Hospital, Rugao, Jiangsu, China

Fudan University- the People's hospital of Rugao Joint Research Institute of Longevity and Aging, China

Xue-Hui Sun

State Key Laboratory of Genetic Engineering and MOE Key Laboratory of Contemporary Anthropology, School of Life Science and Institutes of Biomedical Sciences, Fudan University, Shanghai, China

Xiao-Feng Wang

Fudan University- the People's hospital of Rugao Joint Research Institute of Longevity and Aging, China

Human Phenome Institute, Fudan University, 825 Zhangheng Road, Shanghai, China

National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China

Zheng-Dong Wang

Rugao People’s Hospital, Rugao, Jiangsu, China

Xiao-Yan Jiang

State Key Laboratory of Cardiology, Department of Pathology and Pathophysiology, School of Medicine, Tongji University, Shanghai 200092, China

DOI: 10.15761/BGG.1000150

Article
Article Info
Author Info
Figures & Data

Abstract

Background: To explore the associations of several genetic variants identified in the Genome-Wide Association Studies (GWAS) of European ancestry with mild renal impairment Glomerular Filtration Rate (GFR) in Chinese Han population.

Methods: Data of 1788 community-dwelling elders from the baseline survey of the ageing arm of the Rugao Longevity and Ageing Study was used. Plasma creatinine based GFR was estimated using the eGFR-EPI equations.

Results: Of the 10 common polymorphisms identified in GWAS of the European ancestry, rs17319721 located in the first intron of the SHROOM3, was associated with GFR. A allele was associated with both decreased GFR level and greater odds of mild renal impairment (OR 1.12, 95% CI 1.01-1.23, p = 0.029) defined by GFR < 90 mL/min/1.73 m2 after adjusting for multiple confounds of chronic kidney disease. In addition, compared with rs17319721-GG genotype, AA was associated with both higher depressive score and greater risk of depression prevalence, showing a pleiotropic effects of rs17319721. However, we didnot found significant association of GFR levels with another 42 common polymorphisms that was previously reported to be associated with the traditional risk factors of kidney diseases.

Conclusion: SHROOM3-rs17319721is associated with GFR levels, kidney impairment, and depressive symptoms in a Chinese population.

Keywords

GFR, SHROOM3, polymorphism, genetic association study, Chinese population

Introduction

Glomerular Filtration Rate (GFR)-defined Chronic Kidney Disease (CKD) is a complex diseasewith a heritability of 30-70% [1,2]. Understanding genetic predisposition to CKD is one approach to uncover underlying pathophysiological mechanisms for improved classification and targeted therapies. Over the past decade, Genome-Wide Association Studies (GWAS), a main population-based strategyto screengenetic risk factors, have identified a batch of CKD loci mainly in individuals of European ancestry [3,4].

Recently, in GWAS conducted in the European populations, Köttgen, et al. [5,6] and Chambers, et al. [5-7] identified 15 new loci affecting GFR and/ or CKD (Supplement Table 1). According to the 1000genomes database [8], 10 of these Single Nucleotide Polymorphisms (SNPs) had a Minor Allele Frequency (MAF) greater than 5% in Chinese Han population. They are GCKR-rs1260326, TFDP2-rs347685, SHROOM3-rs17319721, DAB2-rs11959928, SLC34A1-rs6420094, VEGFA-rs881858, PIP5K1B-rs4744712, DACH1-rs626277, UBE2Q2-rs1394125, and SLC7A9-rs12460876. Some of these SNP-GFR associations were replicated in African Americans, highlighting similarity of the genetic variants across ethnicities [9]. Therefore, here we aimed to test whether these CKD associated variants observed in Europeans are still associated with CKD in Chinese Han population. In addition, hypertension, diabetes, dyslipidemia, and obesity are traditional environmental risk factors of CKD [10,11]. In this study, we also observed the effects of some polymorphisms (some is which are functional variants) which was related to hypertension, diabetes, dyslipidemia, or obesity in previous studies [12-16] on renal impairment in Chinese population.

Table 1: Descriptive characteristics of the study subjects and univariate analysis for eGFR.

Characteristics

All participants

(n = 1788)

Mild renal impairment

group (n = 995)

Normal

group(n = 793)

p

Age (years)

75.36 ± 3.907

76.75 ± 3.88

73.62 ± 3.17

< 0.001

Female (%)

958 (53.6%)

509 (51.2%)

449 (56.6%)

0.021

Educated (%)

818 (46.5%)

521 (53.5%)

419 (53.4%)

0.984

Current married (%)

1167 (65.7%)

616 (62.5%)

551 (69.8%)

0.001

Life satisfied (%)

Cigarette smoking

1531 (86.5%)

851 (86.5%)

680 (86.5%)

0.985

Current smoking

255 (14.4%)

143 (14.6%)

122 (14.2%)

0.020

Former smoking

195 (11.1%)

126 (12.9%)

69 (8.8%)

No smoking

1314 (74.5%)

709 (72.5%)

605 (77.0%)

Alcohol drinking

Current drinking

332 (18.8%)

818 (46.5%)

818 (46.5%)

0.459

Former drinking

184 (10.4%)

109 (11.1%)

75 (95%)

No drinking

1251 (70.8%)

684 (69.7%)

567 (72.0%)

BMI (kg/m2)

24.10 ± 3.54

24.23 ± 3.58

23.94 ± 3.49

0.094

SBP (mmHg)

155.72 ± 22.25

156.37 ± 22.87

154.91 ± 21.43

0.172

DBP (mmHg)

81.91 ± 11.52

82.31 ± 11.97

81.41 ± 10.94

0.101

TG (mM)

1.40 ± 0.99

1.44 ± 0.99

1.35 ± 0.98

0.048

Total cholesterol (mM)

5.12 ± 0.95

5.12 ± 0.97

5.12 ± 0.92

0.828

HDL-C (mM)

1.47 ± 0.33

1.44 ± 0.31

1.50 ± 0.34

< 0.001

LDL-C (mM)

2.79 ± 0.72

2.79 ± 0.73

2.80 ± 0.70

0.792

Glucose (mmol/L)

5.86 ± 1.67

5.82 ± 1.68

5.90 ± 1.67

0.354

GFR (mL/min/1.73 m2)

87.21 ± 10.52

80.93 ± 9.84

95.10 ± 4.01

< 0.001

Methods

Study population

Baseline survey data of the ageing arm of Rugao longevity Ageing Study (RuLAS) was used in this study. As described elsewhere [17,18], 1,788 older adults aged 70-84 were recruited at baseline in Nov.-Dec. of 2014 from 31 communities of Jiang’an Township, Rugao city, according to 5-year age and gender strata. Follow-up survey was conducted 1.5 year later (Apri.-Jun. 2016, wave 2) and 3 year later (Nov.–Dec. 2017, wave 3) for repeated measurements of baseline variables and for morbidity and mortality data collections.The Human Ethics Committee of Fudan University School of Life Sciences approved the research. Written consent was obtained from all participants prior to participation.

Genotyping

Genomic DNA was extracted from EDTA anticogulated peripheral blood using a standard method. The aforementioned polymorphisms were genotyped. Primei online 3 (Version 0.040) and Oligo (Version 6.31) software were used to design specific primers. For each sample, genomic DNA (10 ng) was amplified and purified by three-round multiplex PCR following the recommendations of the manufacturer [19] and then purified PCR products mix was processed on a OneTouch 2 instrument and enriched on a OneTouch 2 ES station. Then the oligonucleotide mix was sequenced on a 318 chip using the Ion Torrent PGM and the Ion PGMTM Sequencing 200 Kit v2 according to the manufacturer’s instructions. Original sequencing reads were exported to FASTQ files, the index and adapter sequence were trimed out by using cut adapt software, and BWA v0.7.12 was then used to align the targeted sequence to the SNP reference sequences (NCBI, dbSNP build 142) to generate SAM file. By using samtools, the sam file was transferred to mpileup file, and SNP locus were identified according to Ligase Detection Reaction (LDR). All the genotyping success rates of these loci were > 95%. To assess reproducibility, 5% of samples were analyzed in duplicate and the genotypes were 100% concordant for these samples.

Outcome measurements

Plasma creatinine based GFR was estimated using the following equations: eGFR-EPI =144 × (serum creatinine [mg/dl]/0.7)-0.329 × (0.993)age if female and serum creatinine ≤ 0.7) or eGFR-EPI =144 × (serum creatinine [mg/dl]/0.7)-1.209 × (0.993)age if female and serum creatinine > 0.7) or eGFR-EPI =141 × (serum creatinine [mg/dl]/0.9)-0.411 × (0.993)age if male and serum creatinine ≤ 0.9) or eGFR-EPI =141 × (serum creatinine [mg/dl]/0.9)-1.209 × (0.993)age if male and serum creatinine > 0.9) [20]. Since the GFR of most participants is greater than 60 mL/min/1.73 m2, we categorized them into mild renal impairment group (GFR<90 mL/min/1.73 m2 group, category G1), or normal group (GFR ≥ 90 mL/min/1.73 m2 group) [21].

Depressive symptoms were assessed using the 15-item version of the Geriatric Depression Scale (GDS-15) with a score of 0-15. A score of ≥ 5 was considered depression symptoms. The cut-off score of ≥ 5 has a sensitivity of 0.97 and a specificity of 0.95 [22,23].

Covariates

Covariates in this study include age, gender (male, female), educated (yes or no), marriage status (current married, other [never married, divorced, separated, or widowed]), cigarette smoking (current smoking, former smoking, or no smoking), alcohol drinking (current drinking, former drinking, or no drinking), life satisfaction (satisfied [very satisfied, satisfied, or fair] and unsatisfied [unsatisfied or very unsatisfied]), levels of Body Mass Index (BMI), Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), glucose, total cholesterol, High Density Lipoprotein (HDL), Low Density Lipoprotein (LDL), and triglyceride (TG).

Statistical analysis

Characteristics were presented as the mean ± Standard Deviation (SD) or the percentage. The deviation from Hardy–Weinberg expectation for the genetic variants was tested by a chi-square statistic.

Comparisons of continuous variables were tested using a Student’s t test or ANOVA. The effects of genetic variants on GFR level were examined using ANOVA, adjusting for multiple covariates. Logistic regression models were used to estimate Odds Ratios (ORs) and 95% confidence interval (95% CI) for renal impairment and depressive symptoms, adjusting for multiple confounding factors. A p-value of less than 0.05 (two-tailed) was considered to be statistically significant. All data analysis was done by SPSS 19.0 software (SPSS Inc., Chicago, IL, USA).

Results

Table 1 summarizes the characteristics of the 1788 individuals included in this study. The mean age of the study participants was 75.36 ± 3.91 years, and 53.6% was female. The GFR levels of the renal impairment group and normal group were 80.93 ± 9.84 and 95.10 ± 4.01, respectively. GFR decrease group was older, had less females, less coupled individuals and more smokers, with a higher TG level and a lower HDL-C level (Table 1). The genotype distributions of the studied polymorphisms ranged from 5.1% to 47.8% (Table 2 and Supplemental Table 2).

Table 1: Descriptive characteristics of the study subjects and univariate analysis for eGFR.

Characteristics

All participants

(n = 1788)

Mild renal impairment

group (n = 995)

Normal

group(n = 793)

p

Age (years)

75.36 ± 3.907

76.75 ± 3.88

73.62 ± 3.17

< 0.001

Female (%)

958 (53.6%)

509 (51.2%)

449 (56.6%)

0.021

Educated (%)

818 (46.5%)

521 (53.5%)

419 (53.4%)

0.984

Current married (%)

1167 (65.7%)

616 (62.5%)

551 (69.8%)

0.001

Life satisfied (%)

Cigarette smoking

1531 (86.5%)

851 (86.5%)

680 (86.5%)

0.985

Current smoking

255 (14.4%)

143 (14.6%)

122 (14.2%)

0.020

Former smoking

195 (11.1%)

126 (12.9%)

69 (8.8%)

No smoking

1314 (74.5%)

709 (72.5%)

605 (77.0%)

Alcohol drinking

Current drinking

332 (18.8%)

818 (46.5%)

818 (46.5%)

0.459

Former drinking

184 (10.4%)

109 (11.1%)

75 (95%)

No drinking

1251 (70.8%)

684 (69.7%)

567 (72.0%)

BMI (kg/m2)

24.10 ± 3.54

24.23 ± 3.58

23.94 ± 3.49

0.094

SBP (mmHg)

155.72 ± 22.25

156.37 ± 22.87

154.91 ± 21.43

0.172

DBP (mmHg)

81.91 ± 11.52

82.31 ± 11.97

81.41 ± 10.94

0.101

TG (mM)

1.40 ± 0.99

1.44 ± 0.99

1.35 ± 0.98

0.048

Total cholesterol (mM)

5.12 ± 0.95

5.12 ± 0.97

5.12 ± 0.92

0.828

HDL-C (mM)

1.47 ± 0.33

1.44 ± 0.31

1.50 ± 0.34

< 0.001

LDL-C (mM)

2.79 ± 0.72

2.79 ± 0.73

2.80 ± 0.70

0.792

Glucose (mmol/L)

5.86 ± 1.67

5.82 ± 1.68

5.90 ± 1.67

0.354

GFR (mL/min/1.73 m2)

87.21 ± 10.52

80.93 ± 9.84

95.10 ± 4.01

< 0.001

The association analysis results of the 10 selected SNPs identified in the GWAS of the European ancestry was presented in Table 2. Significant difference of GFR levels was observed across three DAB2-rs11959928 genotypes and a boardline significant difference of GFR levels was observed across three SHROOM3-rs17319721 genotypes. However, since the GFR level of the heterozygote of 11959928is the highest among three genotypes, therefore, we did not further analyze this variant.

Table 2: GFR levels across genotypes of studied polymorphisms in Rugao cohort population.

SNPs

Gene

MAF in this study

Percentages

GFR levels

P

Maj/ Het/ Min

Major homo

Heterozygote

Minor homo

rs1260326

GCKR

T/C= 44.2

30.7/50.2/19.1

86.87 ± 10.53

87.71 ± 9.86

86.86 ±11.54

0.243

rs347685

TFDP2

A/C=29.3

49.9/41.6/8.5

86.87 ± 10.66

87.68 ± 10.36

87.92 ± 9.80

0.240

rs17319721

SHROOM3

G/A=9.10

82.8/16.2/1.0

87.54 ± 10.25

85.98 ± 11.39

85.31 ±12.76

0.055

rs11959928

DAB2

T/A=12.5

76.5/22.0/1.5

86.99 ± 10.70

88.31 ± 9.44

83.60 ± 13.54

0.020

rs6420094

SLC34A1

A/G=27.2

52.3/41.0/6.8

87.18 ± 10.55

87.27 ± 10.50

87.82 ± 9.28

0.827

rs881858

VEGFA

A/G=17.5

68.7/27.7/3.6

87.16 ± 10.39

87.85 ± 10.53

85.73 ± 11.33

0.232

rs4744712

PIP5K1B

C/A=47.8

27.0/50.4/22.6

87.33 ± 11.18

87.32 ± 10.00

87.10 ± 10.46

0.937

rs626277

DACH1

C/A=10.2

80.8/18.0/1.2

87.26 ± 10.45

87.31 ± 10.17

87.22 ± 13.08

0.996

rs1394125

UBE2Q2

G/A=10.2

80.7/18.1/1.1

87.29 ± 10.40

87.55 ± 10.54

84.83 ± 11.82

0.540

rs12460876

SLC7A9

C/T=28.8

50.7/41.2/8.2

87.32 ± 10.26

87.46 ± 10.65

85.96 ± 11.42

0.319

SHROOM3-rs17319721 was associated with both GFR levels and odds of renal impairment defined by GFR < 90 mL/min/1.73 m2, after adjusting for multiple confounds of CKD including adjusted for age, sex, education, marriage, smoking, alcohol drinking, life satisfaction, BMI, SBP, SBP, glucose, TG, HDL, and LDL levels (Table 3). A allele was associated with both decreased GFR level (85.95 ± 11.45mL/min/1.73 m2 vs. 87.54 ± 10.25 mL/min/1.73 m2 for GA+AA and GG carriers, respectively) and greater odds of GFR decrease (OR 1.12, 95% CI 1.01-1.23, p = 0.029) defined by GFR < 90 mL/min/1.73 m2, compared with GG genotype. In addition, compared with rs17319721-GG genotype, AA was associated with both higher depressive score (4.06 ± 3.49 vs. 2.52 ± 2.37) and greater risk of depression prevalence (OR 3.304, 95% CI 1.02-10.74), showing a pleiotropic effects of rs17319721 (Table 4).

Table 3: Associations of SHROOM3-rs17319721 with GFR levels and odds of renal impairment.

GFR levels

Renal impairment

No, GFR ≥ 90 (n, /%)

Yes, GFR < 90 (n, /%)

GG

87.54 ± 10.25

657 (85.0)

780 (81.0)

GA+AA

85.95 ± 11.45

116 (15.0)

183 (19.0)

GA+AA vs GG

p

OR (95% CI), p

Crude model

0.017

1.10(1.01-1.20), 0.029

Model1

0.029

1.11(1.01-1.22), 0.032

Model2

0.038

1.11(1.01-1.22), 0.036

Model3

0.019

1.12(1.01-1.23), 0.029

Model1: adjusted for age and sex.

Model2: adjusted for age, sex, education, marriage, smoking, alcohol drinking, and life satisfaction.

Model3: adjusted for age, sex, education, marriage, smoking, alcohol drinking, life satisfaction, BMI, SBP, SBP, glucose, TG, HDL, and LDL levels.

Table 4: Associations of SHROOM3-rs17319721 with depressive score and odds of levels and odds of depression.

Genotype

Depressive score

Depression

GDS ≥ 5 (n, /%)

GDS < 5 (n, /%)

GG

2.52 ± 2.37

196 (80.3%)

1240 (83.2%)

GA

2.63 ± 2.42

42 (17.2%)

240 (16.1%)

AA

4.06 ± 3.49

6 (2.5%)

11 (0.7%)

GA vs. GG

p

OR (95% CI)

Crude model

0.580

1.107 (0.77-1.59)

Model1

0.623

1.095 (0.76-1.58)

Model2

0.916

0.979 (0.65-1.47)

Model3

0.803

0.948 (0.62-1.44)

AA vs. GG

p

OR (95% CI), p

Crude model

0.016

3.451 (1.26-9.44)

Model1

0.012

3.689 (1.33-10.24)

Model2

0.033

3.500 (1.11-11.06)

Model3

0.047

3.304 (1.02-10.74)

Model1: adjusted for age and sex.

Model2: adjusted for age, sex, education, marriage, smoking, alcohol drinking, and life satisfaction.

Model3: adjusted for age, sex, education, marriage, smoking, alcohol drinking, life satisfaction, BMI, SBP, SBP, glucose, TG, HDL, and LDL levels.

 

Supplemental Table 1: Genomic information of the candidate SNPs.

Gene (chromosome)

SNP

Major/Minor allele

SNP function

MAF in

1000genomics database

GCKR(2p23)

rs1260326

T/C

Nonsynonymous

50%

TFDP2(3q23)

rs347685

A/C

unknown

25.7%

SHROOM3(4q21.1)

rs17319721

G/A

Intronic

10.5%

DAB2(5p13)

rs11959928

T/A

Intronic

15.2%

SLC34A1(5q35)

rs6420094

A/G

Intronic

18.6%

VEGFA(6p12)

rs881858

A/G

Intergenic

19.5%

PIP5K1B(9q13)

rs4744712

C/A

Intronic

50.0%

DACH1(13q22)

rs626277

C/A

Intronic

11.9%

UBE2Q2(15q24.2)

rs1394125

G/A

Intronic

7.62%

SLC7A9(19q13.1)

rs12460876

C/T

Intronic

32.4%

ANXA9/LASS2(1q21.3)

rs267734

T/C

Upstream

2.86%

RKAG2(7q36.1)

rs7805747

G/A

Intronic

0%

UMOD(16p12.3)

rs12917707

G/T

Upstream

0.95%

ALMS1/NAT8 (2p13)

rs13538

A/G

Nonsynonymous

0.48%

ATXN2/SH2B3(12q24.1)

rs653178

T/C

Intronic

0.48%

PRKAG2 (7q36.1)

rs7805747

G/A

Intronic

0%

Supplemental Table 2: Association analyses between CKD risk factor related loci and GFR levels.

GFR levels

Gene

SNPs

Pathway

Clinical significance

MAF

Maj/ Het/ Min

Major hom

Hetero-zygote

Minor hom

p

LPA

rs6415084

Lipid metabolism

Intron variant

11.0

79.1/20.0/1.0

87.23±10.57

87.06±10.42

88.26±7.57

0.886

APOA5

rs662799

Lipid metabolism

-1131T > C,

Statin-response

28.1

51.7/40.3/8.0

87.50±10.49

87.11±10.36

85.93±11.52

0.240

LIPG

rs34474737

Lipid metabolism

Intron variant

29.5

49.4/42.1/8.4

87.21±10.11

87.34±10.72

86.48±12.20

0.661

CETP

rs5882

Lipid metabolism

Val422Ile

47.1

28.3/49.2/22.5

87.05±10.09

86.93±10.66

87.95±10.67

0.274

APOE

rs10402271

Lipid metabolism

Intergenic

15.7

70.9/26.8/2.3

87.19±10.89

87.49±9.49

85.97±9.86

0.651

PCSK9

rs11206510

Lipid metabolism

Intergenic

6.2

87.9/11.7/0.4

87.42±10.23

86.12±12.19

91.54±9.26

0.143

PCSK9

rs2479409

Lipid metabolism

Upstream variant

29.4

50.3/40.6/9.1

87.29±10.57

87.09±10.55

87.41±10.23

0.909

HMGCR

rs12916

Lipid metabolism

3'-UTR

47.4

28.5/48.2/23.3

87.20±10.38

86.96±10.79

88.04±10.00

0.231

HMGCR

rs3846663

Lipid metabolism

Intron variant

47.4

28.5/48.2/23.3

87.17±10.36

86.97±10.77

88.19±9.78

0.146

TIMD4

rs1501908

Lipid metabolism

Intergenic

26.4

54.7/37.9/7.5

87.22±10.52

87.46±10.28

86.79±11.61

0.778

CRP

rs1205

Inflammation

3'-UTR

42.6

33.1/48.6/18.3

87.50±10.39

87.20±10.69

86.46±10.59

0.366

CRP

rs3093059

Inflammation

Upstream variant

17.1

68.5/28.7/2.7

87.35±10.35

87.00±10.82

86.47±11.65

0.725

IL6

rs1800796

Inflammation 

Intron variant

27.9

52.3/39.7/8.0

87.47±10.39

87.08±10.65

86.77±10.43

0.645

IL6

rs1524107

Inflammation

Intron variant

28.8

51.2/40.1/8.7

87.55±10.41

87.05±10.53

86.53±11.19

0.444

TNF-α

rs1799724

Inflammation

-857C> T

14.2

73.4/24.9/1.7

87.25±10.43

87.43±10.58

85.48±13.12

0.626

ALDH2

rs671

Acetaldehyde metabolism

Glu504Lys

Drug-response

23.3

58.3/36.7/5.0

86.98±10.77

87.71±10.25

87.30±9.26

0.398

FTO

rs9939609

Energy metabolism

Intron variant

12.6

76.2/22.5/1.3

87.34±10.70

86.72±10.08

86.15±10.85

0.526

XYLB

rs17118

Energy metabolism

Missense variant

26.4

53.4/40.4/6.2

87.08±10.29

87.46±10.80

87.54±10.33

0.745

GCK

rs4607517

Glucose metabolism

Intergenic

23.2

58.4/36.9/4.7

86.76±10.98

87.84±9.79

87.83±10.49

0.104

NPPB

rs198389

Regulate blood pressure

‑381T>C

13.6

74.9/23.1/2.0

86.97±10.53

87.86±10.80

87.35±8.80

0.332

MTHFR

rs1801131

Regulate blood pressure

Glu429Ala

gene deficiency

16.9

69.1/28.1/2.8

87.01±10.87

87.76±9.63

87.90±9.40

0.374

MTHFR

rs1801133

Regulate blood pressure

Ala222Val

Gene deficiency

44.4

30.4/50.4/19.2

87.59±10.69

87.08±10.55

86.83±10.39

0.530

MTR

rs1805087

Regulate blood pressure

Asp919Gly

10.7

79.8/19.1/1.1

87.31±10.66

86.99±10.04

87.85±4.94

0.857

MTRR

rs1801394

Regulate blood pressure

Ile22Met

Drug-response

24.7

56.8/36.9/6.3

87.30±10.75

86.94±10.46

88.91±7.89

0.194

MTRR

rs2287780

Regulate blood pressure

Arg415TCys

17.5

68.3/28.5/3.2

87.20±10.44

87.50±10.64

86.29±9.71

0.681

MTRR

rs162036

Regulate blood pressure

Lys350Arg

18.6

65.6/31.7/2.7

87.56±10.33

86.83±10.76

85.15±11.48

0.153

BHMT

rs3733890

Regulate blood pressure

Arg239Gln

29.9

49.4/41.5/9.1

87.68±10.05

87.05±10.66

86.52±11.25

0.311

CYP19A1

rs10046

Estrogen biosynthesis

Intron variant

45.3

30.4/48.7/21.0

87.13±10.03

87.37±10.81

87.25±10.47

0.922

CYP19A1

rs1008805

Estrogen biosynthesis

Intron variant

30.3

48.6/42.1/9.3

87.64±10.13

86.88±10.97

87.05±9.88

0.340

ESR1

rs722208

Transcription factor

Intron variant

46.5

29.5/47.9/22.6

87.59±10.12

87.35±10.58

86.77±10.51

0.493

ESR1

rs2175898

Transcription factor

Intron variant

43.9

31.1/50.1/18.8

87.72±9.94

87.17±10.35

86.91±11.48

0.485

ESR2

rs1256031

Transcription factor

Intron variant

42.7

31.8/50.9/17.3

87.41±10.91

87.19±10.31

86.82±10.73

0.749

HNF1A

rs7953249

Transcription factor

Intergenic

47.0

28.7/48.4/22.8

87.70±10.38

87.08±10.42

87.02±10.74

0.516

CDKN2A/B

rs2383207

Regulate gene expression

Intron variant

32.7

45.1/44.5/10.4

87.58±10.22

87.00±10.82

87.16±9.75

0.545

VDR

rs2228570

Calcium homeostasis

Initiator codon, Drug-response

46.0

29.7/48.6/21.7

86.85±10.83

87.29±10.50

87.49±9.98

0.637

VDR

rs1544410

Calcium homeostasis

Intron variant

5.1

90.1/9.7/0.2

87.27±10.48

87.34±10.62

89.59±11.79

0.905

MMP12

rs660599

Tissue remodeling

Intergenic

14.1

74.4/23.1/2.5

87.31±10.69

87.33±9.65

87.32±10.13

1.000

ACTN3

rs1815739

Muscle contraction

Stop gained,

Gene deficiency

39.9

36.6/47.0/16.4

86.80±10.46

87.38±10.62

87.39±10.62

0.535

C1orf112

rs10489177

Catalyze methyl transfer

Upstream variant

18.1

67.7/28.4/3.9

87.29±10.54

86.99±10.58

88.60±8.64

0.489

ABO

rs505922

Catalyze carbohydrate transfer

Intron variant

47.0

27.7/50.8/21.6

87.50±10.06

86.94±10.83

87.61±10.27

0.486

FOXO3A

rs2802292

Transcriptional activator

Intron variant

25.0

55.8/38.4/5.8

86.91±10.82

87.53±10.33

88.28±8.72

0.297

SIRT6

rs352493

DNA repair

Ser46Thr

26.9

53.3/39.5/7.1

87.56±10.25

86.92±10.89

86.28±10.51

0.280

We did not found significant association of GFR levels with 42 common polymorphisms that was previously reported associated with hypertension, diabetes, dyslipidemia, or obesity, which is the established risk factors of CKD (Supplement Table 2).

Discussion

Previously, SHROOM3-rs17319721 was found associated with GFR in the European ancestry.In the present study, we found that SHROOM3-rs17319721 is associated with GFR levels and kidney impairment in another race-Chinese Han population. In addition, for the first time, we found that rs17319721was associated with depressive symptoms. However, we didnot found significant association of GFR levels with another 42 common polymorphisms that was previously associated with the traditional risk factors of kidney diseases.

Population studies of the SHROOM3-rs17319721

Encoded by SHROOM3, shroom3 is an actin binding protein which regulate cell morphology by coordinating the assembly of cytoskeleton [24]. In 2009, Kottgen, et al. conducted the first GWAS of GFR in Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium found that the minor A allele of the SHROOM3-rs17319721 was associated with an decreased eGFRcre level and increased risk of CKD [6]. The association of rs17319721 with eGFRcre was also found in another larger GWAS conducted in European ancestry populations [5] and replicated in the clinical epidemiology follow-up studies conducted in European populations [4,25,26].In the present study, we replicated this association in Chinese population.

However, rs17319721-GFR association was not detected among participants of African ancestry [9], suggesting that allelic heterogeneity exists across ethnicities. For SHROOM3-rs17319721, the MAF is indeed quite different across different ethnic groups, ranging from 43.9% in Europeans, to 21.7% in Africans, and 10.4% in Chinese Han population [8].

Although SHROOM3 rs17319721-A allele decreases GFR and increases the risk of kidney impairment, it was associated with lower albuminuria [27]. The pleiotropic and contradiction association of this gene with GFR and albuminuria may be due to different etiology between them (albuminuria was associated with more smoking, diabetes and elevated triglycerides [28]), different genetic correlations between them [29], and the less coexist of them in early kidney disease [27,30].

At personalized treatment researches, SHROOM3-rs17319721 was found to influence allograft injury. The presence of the SHROOM3 risk A allele in the donor correlated with increasedallograft fibrosis and with reduced GFR at 12 months after transplant [31]. In 189 Chinese patients, Yan, et al. found that rs17319721-A allele carriers had a significantly higher GFR levels than GG genotype from month 1 to month 6 after transplantation [32]. In allografts of US patients, rs17319721 AA was associated with reduced albuminuria by 2 years after transplant [33].

Possible mechanisms link SHROOM3-rs17319721 to CKD

SHROOM3 interacts with FYN via SH3-binding domain to regulate FYN activationand downstream signaling, and maintenances podocyte actin cytoskeleton and phenotype [33]. Rs17319721 is located in the first intron of the high conserved region of the SHROOM3 gene.Rs17319721 A allele is associated with an increased expression of the SHROOM3 than GG genotype. The sequence containing rs17319721-A allele is a TCF7L2 (transcription factor 7-like 2) dependent enhancer that increases SHROOM3 transcription, and then promotes profibrotic gene expression by facilitating TGF-β1/SMAD3 signaling pathway [31]. In podocypes, AA preserves interaction with FYN, activates FYN kinase (Y418 phosphorylation), and stabilizes actin cytoskeleton [33]. In addition, rs17319721-A allele results in an elevated expression of a shorter iso form lacking the PDZ domain [34].

SHROOM3-rs17319721 variant and psychological traits

Since multiple lines of evidence are consistent with wide spread pleiotropy for complex traits that many segregating variants affect multiple traits [35], we further explore whether pleiotropy effects exist for SHROOM3-rs17319721 in our cohort population. For 17319721, it was not only associated with eGFR/CKD in the general populations [5,6,36], but also associated with GFR in the diabetes patients [37] and associated with allograft fibrosis in renal transplant patients [31,38]. In this study, we not only found the association of SHROOM3-rs17319721with GFR, but also with depressive symptoms and risk of depression.

Genetic variant of the SHROOM3 was indeed previously related to psychological traits. In a GWAS conducted in Europeans, rs12513013 and rs12509930 of the SHROOM3 were associated with neuroticism [39]. In the participants of the New England Centenarian Study, Bae, et al. replicated the association of rs12509930 with neuroticism [40]. In the present study, we found that SHROOM3-rs 17319721 was associated with depressive symptoms. The mechanisms that rs17319721 is simultaneously associated with kidney disease and psychological traits are unknown at this stage, but previous studies showed that kidney impairment was linked to psychological traits including lower Quality of Well-Being [41], mental health impairment [42], depression and suicidal ideation [43,44].

CKD risk factor-related loci and kidney impairment

In the present study, we also explored the association of a batch of CKD risk factor-related loci with GFR in our cohort population. Among them, GCKR (Glucokinase regulatory protein) is another pleiotropic gene, the protein of which inhibits hepatic glucokinase.Common variants in GCKR was previously associated with a variety of risk factors of CKD, including serum triglycerides, fasting glucose, C-reactive protein, and diabetes [12]. This locus was associated with GFR in the GWAS of European ancestry [5]. However, in the present study, we did not found significant association between the variant of this locus with GFR level and kidney impairment. In addition, another pleiotropic locus, NPPB was associated with both blood pressure [16] and GFR [45] in previous large GWA studies. However, a functional variant of NPPB, rs198389 (‑381T>C), was not associated with GFR or kidney impairment in our study (Supplement Table 2). Insufficient statistical power resulting from the relative small sample size of the present study may account for the insignificant association.

Conclusions

SHROOM3-rs17319721-A allele was associated with decreased GFR level and greater odds of mild renal impairment in a Chinese population. AA genotypes was also associated with higher depressive score and greater risk of depression prevalence, suggesting a pleiotropic effects of rs17319721. Since the sample size of this study is relatively small, the associations need to be validated in other larger population studies.

Acknowledgments

We acknowledge all participants involved in the present study.

Funding

This work was supported by grants from the Shanghai Municipal Health Commission (202340287),the National Key R&D Program of China (2018YFC2002000), Shanghai Clinical Research Center for Aging and Medicine(19MC1910500)and Shanghai Municipal Science and Technology Major Project (2017SHZDZX01).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict ofinterest.

Ethical approval

The Human Ethics Committee of the School of LifeSciences, Fudan University, Shanghai, People’s Republic of China,approved the present study.

Informed consent

Written informed consent was obtained from allparticipants prior to the study.

References

  1. Seaghdha CMO, Fox CS (2012) Genome-wide association studies of chronic kidney disease: what have we learned? Nat Rev Nephrol 8: 89-99. [Crossref]
  2. Regele F, Jelencsics K, Shiffmanet D, Paré G, McQueen MJ, al. (2015) Genome-wide studies to identify risk factors for kidney disease with a focus on patients with diabetes. Nephrol Dial Transplant 30: 26-33. [Crossref]
  3. Cañadas-Garre M, Anderson K, McGoldrick J, Maxwell AP, McKnight AJ, et al. (2018) Genomic approaches in the search for molecular biomarkers in chronic kidney disease. J Transl Med 16: 292. [Crossref]
  4. Cañadas-Garre M, Anderson K, Cappa R, Skelly R, Smyth LJ, et al. (2019) Genetic susceptibility to chronic kidney disease - Some more pieces for the heritability puzzle. Front Genet 10: 453. [Crossref]
  5. Köttgen A, Pattaro C, Böger CA, Fuchsberger C, Olden M, et al. (2010) New loci associated with kidney function and chronic kidney disease. Nat Genet 42: 376-384. [Crossref]
  6. Köttgen A, Glazer NL, Dehghan A, Hwang SJ, Katz R, et al. (2009) Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet 41: 712-717. [Crossref]
  7. Chambers JC, Zhang W, Lord GM, Harst P, Lawlor DA, et al. (2010) Genetic loci influencing kidney function and chronic kidney disease. Nat Genet 42: 373-375. [Crossref]
  8. https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/
  9. Liu CT, Garnaas MK, Tin A, Kottgen A, Franceschini N, et al. (2011) Genetic association for renal traits among participants of African ancestry reveals new loci for renal function. PLoS Genet 7: 1002264. [Crossref]
  10. Kazancioglu R (2013) Risk factors for chronic kidney disease: an update. Kidney Int Suppl 4: 368-371. [Crossref]
  11. Taal MW, Brenner BM (2006) Predicting initiation and progression of chronic kidney disease: Developing renal risk scores. Kidney 70: 1694-705. [Crossref]
  12. Prasad RB, Groop L (2015) Genetics of type 2 diabetes-pitfalls and possibilities. Genes (Basel) 6: 87-123. [Crossref]
  13. Albuquerque D, Stice E, Rodríguez-López R, Manco L. Nobrega C (2015) Current review of genetics of human obesity: from molecular mechanisms to an evolutionary perspective. Mol Genet Genomics 290: 1191-1221. [Crossref]
  14. Dai X, Wiernek S, Evans JP, Runge MS (2016) Genetics of coronary artery disease and myocardial infarction. World J Cardiol 8: 1-23. [Crossref]
  15. Khera AV, Kathiresan S (2017) Genetics of coronary artery disease: discovery, biology and clinical translation. Nat Rev Genet 18: 331-344. [Crossref]
  16. Padmanabhan S, Caulfield M, Dominiczak AF (2015) Genetic and molecular aspects of hypertension. Circ Res 116: 937-959. [Crossref]
  17. Liu Z, Wang Y, Zhang Y, Chu X, Wang Z, et al. (2016) Cohort Profile: The Rugao Longevity and Ageing Study (RuLAS). Int J Epidemiol 45: 1064-1073. [Crossref]
  18. Shi GP, Ma T, Zhu YS, Wang ZD, Chu XF, et al. (2019) Frailty phenotype, frailty index and risk of mortality in Chinese elderly population- Rugao longevity and ageing study. Arch Gerontol Geriatr 80: 115-119. [Crossref]
  19. Chen K, Zhou YX, Li K, Qi LX, Zhang QF, et al. (2016) A novel three-round multiplex PCR for SNP genotyping with next generation sequencing. Anal Bioanal Chem 408: 4371-4377. [Crossref]
  20. Levey AS, Stevens LA, Schmid CH, Zhangi YL, Castro AF, et al. (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612. [Crossref]
  21. Stevens PE, Levin A (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158: 825-830. [Crossref]
  22. Nyunt MS, Fones C, Niti M, Ng TP (2009) Criterion-based validity and reliability of the Geriatric Depression Screening Scale (GDS-15) in a large validation sample of community-living Asian older adults. Aging Ment Health 13: 376-382. [Crossref]
  23. Friedman B, Heisel MJ, Delavan RL (2005) Psychometric properties of the 15-item geriatric depression scale in functionally impaired, cognitively intact, community-dwelling elderly primary care patients. J Am Geriatr Soc 53: 1570-1576. [Crossref]
  24. Lee C, Scherr HM, Wallingford JB (2007) Shroom family proteins regulate gamma-tubulin distribution and microtubule architecture during epithelial cell shape change. Development 134: 1431-1441.[Crossref]
  25. Böger CA, Chen MH, Tin A, Oldem M, Kottgen A, et al. (2011) CUBN is a gene locus for albuminuria. J Am Soc Nephrol 22: 555-570. [Crossref]
  26. Sveinbjornsson G, Mikaelsdottir E, Palsson R, Indridason OS, Holm H, et al. (2014) Rare mutations associating with serum creatinine and chronic kidney disease. Hum Mol Genet 23: 6935-6943. [Crossref]
  27. Ellis JW, Chen MH, Foster MC, Liu CT, Larson MG, et al. (2012) Validated SNPs for eGFR and their associations with albuminuria. Hum Mol Genet 21: 3293-3298. [Crossref]
  28. Foster MC, Hwang SJ, Larson MG, Parikh NI, Meigs JB, et al. (2007) Cross-classification of microalbuminuria and reduced glomerular filtration rate: associations between cardiovascular disease risk factors and clinical outcomes. Arch Intern Med 167: 1386-1392. [Crossref]
  29. Leon JM, Freedman B, Miller MB, North KE, Hunt SC, et al. (2007) Genome scan of glomerular filtration rate and albuminuria: the HyperGEN study. Nephrol Dial Transplant 22: 763-771. [Crossref]
  30. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS (2003) Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41: 1-12. [Crossref]
  31. Menon MC, Chuang PY, Li Z, Wei C, Zhang W, et al. (2015) Intronic locus determines SHROOM3 expression and potentiates renal allograft fibrosis. J Clin Invest 125: 208-221. [Crossref]
  32. Yan L, Li Y, Tang JT, An YF, Luo LM, et al. (2017) The influence of living donor SHROOM3 and ABCB1 genetic variants on renal function after kidney transplantation. Pharmacogenet Genomics 27: 19-26. [Crossref]
  33. Wei C, Banu K, Garzon F, Basgen JM, Philippe N, et al. (2018) SHROOM3-FYN Interaction regulates nephrin phosphorylation and affects albuminuria in allografts. J Am Soc Nephrol 29: 2641-2657. [Crossref]
  34. Prokop JW, Yeo NC, Ottmann C, Chhetri SB, Florus KL, et al. (2018) Characterization of Coding/Noncoding Variants for SHROOM3 in Patients with CKD. J Am Soc Nephrol 29: 1525-1535. [Crossref]
  35. Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, et al. (2017) 10 Years of GWAS Discovery:Biology, Function, and Translation. Am J Hum Genet 101: 5-22. [Crossref]
  36. Wuttke M, Köttgen A (2016) Insights into kidney diseases from genome-wide association studies. Nat Rev Nephrol 12: 549-562. [Crossref]
  37. Deshmukh HA, Palmer CNA, Morris AD, Colhoun HM (2013) Investigation of known estimated glomerular fltration rate loci in patients with type 2 diabetes. Diabet Med 30: 1230-1235. [Crossref]
  38. Pattaro C, Köttgen A, Teumer A, Garnaas M, Boger CA, et al. (2012) Genome-wide association and functional follow-up reveals new loci for kidney function. PLoS Genet 8: e1002584. [Crossref]
  39. de Moor MH, Costa PT, Terracciano A, Krueger RF, de Geus EJC, et al. (2012) Meta-analysis of genome-wide association studies for personality. Mol Psychiatry 17: 337-349. [Crossref]
  40. Bae HT, Sebastiani P, Sun JX, Andersen SL, Daw EW, et al. (2013) Genome-wide association study of personality traits in the long life family study. Front Genet 4: 65. [Crossref]
  41. Rocco MV, Gassman JJ, Wang SR, Kaplan RM (1997) Cross-sectional study of quality of life and symptoms in chronic renal disease patients: the Modification of Diet in Renal Disease Study. Am J Kidney Dis 29: 888-896. [Crossref]
  42. Chow FY, Briganti EM, Kerr PG, Chadban SJ, Zimmet PZ, et al. (2003) Health-related quality of life in Australian adults with renal insufficiency: a population-based study. Am J Kidney Dis 41: 596-604. [Crossref]
  43. Martens RJH, Kooman JP, Stehouwer CDA, Dagnelie PC, van der Kallen CJH, et al. (2018) Albuminuria is associated with a higher prevalence of depression in a population-based cohort study: the Maastricht Study. Nephrol Dial Transplant 33: 128-138. [Crossref]
  44. Jhee JH, Lee E, Cha MU, Lee M, Kim H, et al. (2017) Prevalence of depression and suicidal ideation increases proportionally with renal function decline, beginning from early stages of chronic kidney disease. Medicine (Baltimore) 96: 8476 [Crossref]
  45. Gorski M, Tin A, Garnaas M, McMahon GM, Chu AY, et al. (2015) Genome-wide association study of kidney function decline in individuals of European descent. Kidney Int 87: 1017-1029. [Crossref]

Editorial Information

Editor-in-Chief

Hieronim Jakubowski
Rutgers University-New Jersey

Article Type

Research

Publication history

Received date: September 15, 2023
Accepted date: October 09, 2023
Published date: October 12, 2023

Copyright

©2023 Guo-Ping Shi. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation

Guo-Ping Shi, Xue-Feng Chu, Yin-Sheng Zhu, Jiang-Hong Guo, Yong Wang, et al. (2023) Associations of a SHROOM3 variant with mild renal impairment and depressive symptomsin a Chinese Han population. Biomed Genet Genomics 6: doi: 10.15761/BGG.1000150

Corresponding author

Zheng-Dong Wang

Zheng-Dong Wang, Rugao People’s Hospital, Rugao, Jiangsu, China.

Table 1: Descriptive characteristics of the study subjects and univariate analysis for eGFR.

Characteristics

All participants

(n = 1788)

Mild renal impairment

group (n = 995)

Normal

group(n = 793)

p

Age (years)

75.36 ± 3.907

76.75 ± 3.88

73.62 ± 3.17

< 0.001

Female (%)

958 (53.6%)

509 (51.2%)

449 (56.6%)

0.021

Educated (%)

818 (46.5%)

521 (53.5%)

419 (53.4%)

0.984

Current married (%)

1167 (65.7%)

616 (62.5%)

551 (69.8%)

0.001

Life satisfied (%)

Cigarette smoking

1531 (86.5%)

851 (86.5%)

680 (86.5%)

0.985

Current smoking

255 (14.4%)

143 (14.6%)

122 (14.2%)

0.020

Former smoking

195 (11.1%)

126 (12.9%)

69 (8.8%)

No smoking

1314 (74.5%)

709 (72.5%)

605 (77.0%)

Alcohol drinking

Current drinking

332 (18.8%)

818 (46.5%)

818 (46.5%)

0.459

Former drinking

184 (10.4%)

109 (11.1%)

75 (95%)

No drinking

1251 (70.8%)

684 (69.7%)

567 (72.0%)

BMI (kg/m2)

24.10 ± 3.54

24.23 ± 3.58

23.94 ± 3.49

0.094

SBP (mmHg)

155.72 ± 22.25

156.37 ± 22.87

154.91 ± 21.43

0.172

DBP (mmHg)

81.91 ± 11.52

82.31 ± 11.97

81.41 ± 10.94

0.101

TG (mM)

1.40 ± 0.99

1.44 ± 0.99

1.35 ± 0.98

0.048

Total cholesterol (mM)

5.12 ± 0.95

5.12 ± 0.97

5.12 ± 0.92

0.828

HDL-C (mM)

1.47 ± 0.33

1.44 ± 0.31

1.50 ± 0.34

< 0.001

LDL-C (mM)

2.79 ± 0.72

2.79 ± 0.73

2.80 ± 0.70

0.792

Glucose (mmol/L)

5.86 ± 1.67

5.82 ± 1.68

5.90 ± 1.67

0.354

GFR (mL/min/1.73 m2)

87.21 ± 10.52

80.93 ± 9.84

95.10 ± 4.01

< 0.001

Table 2: GFR levels across genotypes of studied polymorphisms in Rugao cohort population.

SNPs

Gene

MAF in this study

Percentages

GFR levels

P

Maj/ Het/ Min

Major homo

Heterozygote

Minor homo

rs1260326

GCKR

T/C= 44.2

30.7/50.2/19.1

86.87 ± 10.53

87.71 ± 9.86

86.86 ±11.54

0.243

rs347685

TFDP2

A/C=29.3

49.9/41.6/8.5

86.87 ± 10.66

87.68 ± 10.36

87.92 ± 9.80

0.240

rs17319721

SHROOM3

G/A=9.10

82.8/16.2/1.0

87.54 ± 10.25

85.98 ± 11.39

85.31 ±12.76

0.055

rs11959928

DAB2

T/A=12.5

76.5/22.0/1.5

86.99 ± 10.70

88.31 ± 9.44

83.60 ± 13.54

0.020

rs6420094

SLC34A1

A/G=27.2

52.3/41.0/6.8

87.18 ± 10.55

87.27 ± 10.50

87.82 ± 9.28

0.827

rs881858

VEGFA

A/G=17.5

68.7/27.7/3.6

87.16 ± 10.39

87.85 ± 10.53

85.73 ± 11.33

0.232

rs4744712

PIP5K1B

C/A=47.8

27.0/50.4/22.6

87.33 ± 11.18

87.32 ± 10.00

87.10 ± 10.46

0.937

rs626277

DACH1

C/A=10.2

80.8/18.0/1.2

87.26 ± 10.45

87.31 ± 10.17

87.22 ± 13.08

0.996

rs1394125

UBE2Q2

G/A=10.2

80.7/18.1/1.1

87.29 ± 10.40

87.55 ± 10.54

84.83 ± 11.82

0.540

rs12460876

SLC7A9

C/T=28.8

50.7/41.2/8.2

87.32 ± 10.26

87.46 ± 10.65

85.96 ± 11.42

0.319

Table 3: Associations of SHROOM3-rs17319721 with GFR levels and odds of renal impairment.

GFR levels

Renal impairment

No, GFR ≥ 90 (n, /%)

Yes, GFR < 90 (n, /%)

GG

87.54 ± 10.25

657 (85.0)

780 (81.0)

GA+AA

85.95 ± 11.45

116 (15.0)

183 (19.0)

GA+AA vs GG

p

OR (95% CI), p

Crude model

0.017

1.10(1.01-1.20), 0.029

Model1

0.029

1.11(1.01-1.22), 0.032

Model2

0.038

1.11(1.01-1.22), 0.036

Model3

0.019

1.12(1.01-1.23), 0.029

Model1: adjusted for age and sex.

Model2: adjusted for age, sex, education, marriage, smoking, alcohol drinking, and life satisfaction.

Model3: adjusted for age, sex, education, marriage, smoking, alcohol drinking, life satisfaction, BMI, SBP, SBP, glucose, TG, HDL, and LDL levels.

Table 4: Associations of SHROOM3-rs17319721 with depressive score and odds of levels and odds of depression.

Genotype

Depressive score

Depression

GDS ≥ 5 (n, /%)

GDS < 5 (n, /%)

GG

2.52 ± 2.37

196 (80.3%)

1240 (83.2%)

GA

2.63 ± 2.42

42 (17.2%)

240 (16.1%)

AA

4.06 ± 3.49

6 (2.5%)

11 (0.7%)

GA vs. GG

p

OR (95% CI)

Crude model

0.580

1.107 (0.77-1.59)

Model1

0.623

1.095 (0.76-1.58)

Model2

0.916

0.979 (0.65-1.47)

Model3

0.803

0.948 (0.62-1.44)

AA vs. GG

p

OR (95% CI), p

Crude model

0.016

3.451 (1.26-9.44)

Model1

0.012

3.689 (1.33-10.24)

Model2

0.033

3.500 (1.11-11.06)

Model3

0.047

3.304 (1.02-10.74)

Model1: adjusted for age and sex.

Model2: adjusted for age, sex, education, marriage, smoking, alcohol drinking, and life satisfaction.

Model3: adjusted for age, sex, education, marriage, smoking, alcohol drinking, life satisfaction, BMI, SBP, SBP, glucose, TG, HDL, and LDL levels.

 

Supplemental Table 1: Genomic information of the candidate SNPs.

Gene (chromosome)

SNP

Major/Minor allele

SNP function

MAF in

1000genomics database

GCKR(2p23)

rs1260326

T/C

Nonsynonymous

50%

TFDP2(3q23)

rs347685

A/C

unknown

25.7%

SHROOM3(4q21.1)

rs17319721

G/A

Intronic

10.5%

DAB2(5p13)

rs11959928

T/A

Intronic

15.2%

SLC34A1(5q35)

rs6420094

A/G

Intronic

18.6%

VEGFA(6p12)

rs881858

A/G

Intergenic

19.5%

PIP5K1B(9q13)

rs4744712

C/A

Intronic

50.0%

DACH1(13q22)

rs626277

C/A

Intronic

11.9%

UBE2Q2(15q24.2)

rs1394125

G/A

Intronic

7.62%

SLC7A9(19q13.1)

rs12460876

C/T

Intronic

32.4%

ANXA9/LASS2(1q21.3)

rs267734

T/C

Upstream

2.86%

RKAG2(7q36.1)

rs7805747

G/A

Intronic

0%

UMOD(16p12.3)

rs12917707

G/T

Upstream

0.95%

ALMS1/NAT8 (2p13)

rs13538

A/G

Nonsynonymous

0.48%

ATXN2/SH2B3(12q24.1)

rs653178

T/C

Intronic

0.48%

PRKAG2 (7q36.1)

rs7805747

G/A

Intronic

0%

Supplemental Table 2: Association analyses between CKD risk factor related loci and GFR levels.

GFR levels

Gene

SNPs

Pathway

Clinical significance

MAF

Maj/ Het/ Min

Major hom

Hetero-zygote

Minor hom

p

LPA

rs6415084

Lipid metabolism

Intron variant

11.0

79.1/20.0/1.0

87.23±10.57

87.06±10.42

88.26±7.57

0.886

APOA5

rs662799

Lipid metabolism

-1131T > C,

Statin-response

28.1

51.7/40.3/8.0

87.50±10.49

87.11±10.36

85.93±11.52

0.240

LIPG

rs34474737

Lipid metabolism

Intron variant

29.5

49.4/42.1/8.4

87.21±10.11

87.34±10.72

86.48±12.20

0.661

CETP

rs5882

Lipid metabolism

Val422Ile

47.1

28.3/49.2/22.5

87.05±10.09

86.93±10.66

87.95±10.67

0.274

APOE

rs10402271

Lipid metabolism

Intergenic

15.7

70.9/26.8/2.3

87.19±10.89

87.49±9.49

85.97±9.86

0.651

PCSK9

rs11206510

Lipid metabolism

Intergenic

6.2

87.9/11.7/0.4

87.42±10.23

86.12±12.19

91.54±9.26

0.143

PCSK9

rs2479409

Lipid metabolism

Upstream variant

29.4

50.3/40.6/9.1

87.29±10.57

87.09±10.55

87.41±10.23

0.909

HMGCR

rs12916

Lipid metabolism

3'-UTR

47.4

28.5/48.2/23.3

87.20±10.38

86.96±10.79

88.04±10.00

0.231

HMGCR

rs3846663

Lipid metabolism

Intron variant

47.4

28.5/48.2/23.3

87.17±10.36

86.97±10.77

88.19±9.78

0.146

TIMD4

rs1501908

Lipid metabolism

Intergenic

26.4

54.7/37.9/7.5

87.22±10.52

87.46±10.28

86.79±11.61

0.778

CRP

rs1205

Inflammation

3'-UTR

42.6

33.1/48.6/18.3

87.50±10.39

87.20±10.69

86.46±10.59

0.366

CRP

rs3093059

Inflammation

Upstream variant

17.1

68.5/28.7/2.7

87.35±10.35

87.00±10.82

86.47±11.65

0.725

IL6

rs1800796

Inflammation 

Intron variant

27.9

52.3/39.7/8.0

87.47±10.39

87.08±10.65

86.77±10.43

0.645

IL6

rs1524107

Inflammation

Intron variant

28.8

51.2/40.1/8.7

87.55±10.41

87.05±10.53

86.53±11.19

0.444

TNF-α

rs1799724

Inflammation

-857C> T

14.2

73.4/24.9/1.7

87.25±10.43

87.43±10.58

85.48±13.12

0.626

ALDH2

rs671

Acetaldehyde metabolism

Glu504Lys

Drug-response

23.3

58.3/36.7/5.0

86.98±10.77

87.71±10.25

87.30±9.26

0.398

FTO

rs9939609

Energy metabolism

Intron variant

12.6

76.2/22.5/1.3

87.34±10.70

86.72±10.08

86.15±10.85

0.526

XYLB

rs17118

Energy metabolism

Missense variant

26.4

53.4/40.4/6.2

87.08±10.29

87.46±10.80

87.54±10.33

0.745

GCK

rs4607517

Glucose metabolism

Intergenic

23.2

58.4/36.9/4.7

86.76±10.98

87.84±9.79

87.83±10.49

0.104

NPPB

rs198389

Regulate blood pressure

‑381T>C

13.6

74.9/23.1/2.0

86.97±10.53

87.86±10.80

87.35±8.80

0.332

MTHFR

rs1801131

Regulate blood pressure

Glu429Ala

gene deficiency

16.9

69.1/28.1/2.8

87.01±10.87

87.76±9.63

87.90±9.40

0.374

MTHFR

rs1801133

Regulate blood pressure

Ala222Val

Gene deficiency

44.4

30.4/50.4/19.2

87.59±10.69

87.08±10.55

86.83±10.39

0.530

MTR

rs1805087

Regulate blood pressure

Asp919Gly

10.7

79.8/19.1/1.1

87.31±10.66

86.99±10.04

87.85±4.94

0.857

MTRR

rs1801394

Regulate blood pressure

Ile22Met

Drug-response

24.7

56.8/36.9/6.3

87.30±10.75

86.94±10.46

88.91±7.89

0.194

MTRR

rs2287780

Regulate blood pressure

Arg415TCys

17.5

68.3/28.5/3.2

87.20±10.44

87.50±10.64

86.29±9.71

0.681

MTRR

rs162036

Regulate blood pressure

Lys350Arg

18.6

65.6/31.7/2.7

87.56±10.33

86.83±10.76

85.15±11.48

0.153

BHMT

rs3733890

Regulate blood pressure

Arg239Gln

29.9

49.4/41.5/9.1

87.68±10.05

87.05±10.66

86.52±11.25

0.311

CYP19A1

rs10046

Estrogen biosynthesis

Intron variant

45.3

30.4/48.7/21.0

87.13±10.03

87.37±10.81

87.25±10.47

0.922

CYP19A1

rs1008805

Estrogen biosynthesis

Intron variant

30.3

48.6/42.1/9.3

87.64±10.13

86.88±10.97

87.05±9.88

0.340

ESR1

rs722208

Transcription factor

Intron variant

46.5

29.5/47.9/22.6

87.59±10.12

87.35±10.58

86.77±10.51

0.493

ESR1

rs2175898

Transcription factor

Intron variant

43.9

31.1/50.1/18.8

87.72±9.94

87.17±10.35

86.91±11.48

0.485

ESR2

rs1256031

Transcription factor

Intron variant

42.7

31.8/50.9/17.3

87.41±10.91

87.19±10.31

86.82±10.73

0.749

HNF1A

rs7953249

Transcription factor

Intergenic

47.0

28.7/48.4/22.8

87.70±10.38

87.08±10.42

87.02±10.74

0.516

CDKN2A/B

rs2383207

Regulate gene expression

Intron variant

32.7

45.1/44.5/10.4

87.58±10.22

87.00±10.82

87.16±9.75

0.545

VDR

rs2228570

Calcium homeostasis

Initiator codon, Drug-response

46.0

29.7/48.6/21.7

86.85±10.83

87.29±10.50

87.49±9.98

0.637

VDR

rs1544410

Calcium homeostasis

Intron variant

5.1

90.1/9.7/0.2

87.27±10.48

87.34±10.62

89.59±11.79

0.905

MMP12

rs660599

Tissue remodeling

Intergenic

14.1

74.4/23.1/2.5

87.31±10.69

87.33±9.65

87.32±10.13

1.000

ACTN3

rs1815739

Muscle contraction

Stop gained,

Gene deficiency

39.9

36.6/47.0/16.4

86.80±10.46

87.38±10.62

87.39±10.62

0.535

C1orf112

rs10489177

Catalyze methyl transfer

Upstream variant

18.1

67.7/28.4/3.9

87.29±10.54

86.99±10.58

88.60±8.64

0.489

ABO

rs505922

Catalyze carbohydrate transfer

Intron variant

47.0

27.7/50.8/21.6

87.50±10.06

86.94±10.83

87.61±10.27

0.486

FOXO3A

rs2802292

Transcriptional activator

Intron variant

25.0

55.8/38.4/5.8

86.91±10.82

87.53±10.33

88.28±8.72

0.297

SIRT6

rs352493

DNA repair

Ser46Thr

26.9

53.3/39.5/7.1

87.56±10.25

86.92±10.89

86.28±10.51

0.280